Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST BRAF V600 substudy of vemurafenib + cobimetinib in BRAF V600-mutant NSCLC and solid tumors
ACTRN12620000861954Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by University of Sydney. Primary endpoints: Disease control in metastatic NSCLC and Disease control in other cancers. Started Jul 2021; status: completed.
02
Drugs
vemurafenibcobimetinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12620000861954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000861954.